

Novavax to Participate in 2024 Jefferies Global Healthcare Conference

May 30, 2024

GAITHERSBURG, Md., May 30, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: [NVAX](#)), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in the 2024 Jefferies Global Healthcare Conference.

Conference Details:

Fireside Chat

Date: Thursday, June 6, 2024

Time: 12:30 – 12:55 p.m. Eastern Time (ET)

Location: New York, NY

Moderator: Roger Song, MD, CFA, Equity Research Analyst – Biotechnology

Novavax participant: John C. Jacobs, President and Chief Executive Officer

Conference

Event: Investor Meetings

Date: Thursday, June 6, 2024

Recordings

A replay of the recorded fireside session will be available through the Events & Presentations page of the Company's website at ir.novavax.com for 30 days from the date of the conference.

About Novavax

Novavax, Inc. (Nasdaq: [NVAX](#)) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. The Company's portfolio includes its COVID-19 vaccine and its pipeline includes COVID-19-Influenza Combination and stand-alone influenza vaccine candidates. In addition, Novavax's adjuvant is included in the University of Oxford and Serum Institute of India's R21/Matrix-M malaria vaccine. Please visit novavax.com and [LinkedIn](#) for more information.

Contacts:

Investors

Erika Schultz
240-268-2022

ir@novavax.com

Media

Giovanna Chandler

240-720-7804

media@novavax.com

SOURCE Novavax, Inc.